Structure-based HIV-1 integrase inhibitor design: a future perspective

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.10, Iss.2, 2001-02, pp. : 281-296

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Structure-Based Inhibitor Design Targeting HIV-1 Integrase

Current Drug Targets - Infectious Disorders, Vol. 2, Iss. 3, 2002-09 ,pp. : 217-234

Bentham Science Publishers

Access to resources Recommend Favorite

Discovery of HIV-1 Integrase Inhibitors through a Novel Combination of Ligand and Structure-based Drug Design

Medicinal Chemistry, Vol. 1, Iss. 3, 2005-05 ,pp. : 263-275

Bentham Science Publishers

Access to resources Recommend Favorite

Raltegravir: an integrase inhibitor for HIV-1

By Evering Teresa H Markowitz Martin

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 413-422

Informa Healthcare

Access to resources Recommend Favorite

Structure and Function of HIV-1 Integrase

Current Topics in Medicinal Chemistry, Vol. 4, Iss. 9, 2004-05 ,pp. : 965-977

Bentham Science Publishers

Access to resources Recommend Favorite

Elvitegravir: a once-daily inhibitor of HIV-1 integrase

By Wills Todd Vega Vivian

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 395-401

Informa Healthcare

Access to resources Recommend Favorite